Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interactions of mood stabilizers].

Rodolfo Zaratiegui

    Vertex (Buenos Aires, Argentina)
    |July 31, 2003
    PubMed
    Summary

    Polypharmacy in bipolar disorder treatment frequently leads to drug-drug interactions with mood stabilizers like lithium and valproate. This review details common interactions and pharmacokinetic factors to guide clinical practice.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Psychiatric disorders in epilepsy: an update].

    Vertex (Buenos Aires, Argentina)·2013
    Same author

    [Validation of the Argentine version of the Mood Disorder Questionnaire].

    Vertex (Buenos Aires, Argentina)·2011
    Same author

    [2nd Argentine consensus on the treatment of bipolar disorders 2010].

    Vertex (Buenos Aires, Argentina)·2011
    Same author

    [STAR* D study: searching strategies regarding lack of response to an SSRI].

    Vertex (Buenos Aires, Argentina)·2009
    Same author

    [Depression and quality of life].

    Vertex (Buenos Aires, Argentina)·2008
    Same author

    Bipolar disorders and affective temperaments: a national family study testing the "endophenotype" and "subaffective" theses using the TEMPS-A Buenos Aires.

    Journal of affective disorders·2007

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy
    • Neuroscience

    Context:

    • Polypharmacy is common in bipolar disorder management.
    • Long-term treatment increases the likelihood of concurrent medical conditions and additional prescriptions.
    • Drug-drug interactions (DDIs) involving mood stabilizers are a significant clinical concern.

    Purpose:

    • To provide a practical and clinically relevant review of DDIs with common mood stabilizers.
    • To highlight pharmacokinetic factors influencing these interactions.
    • To illustrate potential interaction scenarios with clinical vignettes.

    Summary:

    • Reviews key DDIs for lithium, carbamazepine, oxcarbazepine, valproate, lamotrigine, gabapentin, and topiramate.
    • Discusses pharmacokinetic considerations essential for understanding and predicting DDIs.
    • Includes clinical examples to demonstrate real-world interaction risks.

    Impact:

    • Aims to improve the safe and effective use of mood stabilizers in patients with bipolar disorder.
    • Provides clinicians with essential information to anticipate and manage DDIs.
    • Contributes to reducing adverse drug events in complex treatment regimens.

    Related Experiment Videos